End Stage Renal Disease (ESRD) Drug Market 2025–2029: Unveiling Growth Developments with the Latest Updates
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Much Will The End Stage Renal Disease (ESRD) Drug Market Be Worth By 2029?
Recent years have seen a rapid expansion in the market size of drugs for end stage renal disease (esrd). Current expectations indicate this market will expand from $131.41 billion in 2024 to $148.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.0%. This impressive historic growth rate is largely due to factors such as an increase in cases of end stage renal disease, an aging population, better access to healthcare services, governmental initiatives and regulations, and a higher acceptance of renal replacement therapies.
The market size of drugs for end stage renal disease (esrd) is projected to experience swift expansion in the upcoming years. The market is anticipated to reach a valuation of “$262.76 billion by 2029 with a compound annual growth rate (CAGR) of 15.3%. The expansion projected within this period can be tied to factors such as new therapies and drug innovations, an increase in healthcare spending, a growing worldwide prevalence of chronic kidney disorders, the growing trend of personalized medicine, regulatory support, and timely approvals. Key trends for this period include a rising occurrence of end stage renal disease, advancements in treatment techniques, greater focus on precision medicine, the introduction of combined therapies, and technological incorporation in healthcare.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
Which Industry Forces Are Driving The End Stage Renal Disease (ESRD) Drug Market Forward?
The end-stage renal disease (ESRD) drug market is anticipated to experience significant growth due to the increasing prevalence of obesity and diabetes. Obesity is characterized by excessive or abnormal accumulation of fat that presents health risks, while diabetes is a long-term condition that occurs when the body does not produce enough insulin or cannot effectively use the insulin it does produce. Managing fluid, electrolyte levels, blood pressure, and waste product elimination through dialysis in renal disease patients can enhance their general health, potentially leading to weight loss and better blood sugar management. For example, World Obesity, a membership organization based in the US that focuses on obesity research and management, forecasts that the number of obese individuals could increase to 892 million in 2025, and further surge to 1.025 billion in 2030. Moreover, the National Health Service, a UK-based public health service, projects that by 2030, the UK could have up to 5.5 million people with diabetes, affecting nearly 9% of the population. Consequently, the escalating instances of obesity and diabetes are expected to fuel the demand for ESRD drugs.
What Are The Key Segment Trends Observed In The End Stage Renal Disease (ESRD) Drug Market?
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
Which Disruptive Trends Are Driving Change Across The End Stage Renal Disease (ESRD) Drug Market?
Driving the end-stage renal disease (ESRD) drug market’s popularity is the major trend of product innovation. Big players in the ESRD drug market are concentrating on the creation of novel solutions to maintain market relevance. For instance, in April 2022, UK pharmaceutical and biotechnology giant, GlaxoSmithKline PLC, announced that their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was accepted by the US Food and Drug Administration (FDA). The acceptance was for its potential use in treating chronic kidney disease anemia (CKD). This innovative product is rooted in the exceptional Nobel prize-winning research demonstrating how cells perceive and modify to oxygen supply.
Which Firms Are Driving Innovation Within The End Stage Renal Disease (ESRD) Drug Market?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The End Stage Renal Disease (ESRD) Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
